Business
Jenex's TherOZap(TM) Technology Indicates Effectiveness in Inhibiting Zika Virus After Pre-Clinical Study
Toronto, Ontario--(Newsfile Corp. - January 8, 2018) - The Jenex Corporation (TSXV: JEN) ("Jen...
About this update from Therma Bright Inc.
[{"type":"text","content":"Jenex's TherOZap(TM) Technology Indicates Effectiveness in Inhibiting Zika Virus After Pre-Clinical StudyToronto, Ontario--(Newsfile Corp. - January 8, 2018) - The Jenex Corporation (TSXV: JEN) (\"Jenex\" or the \"Company\"), a progressive medical device technology company, today announces that it has received results indicating effectiveness of its TherOZap™ technology in inhibiting the Zika virus.The objectives for Jenex were to engage Techna Institute at UHN in a study to assess Jenex's TherOZap™ technology for the inactivation of live Zika virus in culture media and the inhibition of Zika virus infection into cultured cells in vitro. The study aimed to measure the effect of the TherOZap™ technology on cytopathogenic effect (\"CPE\"), which refers to structural changes in host cells that are caused by viral invasion and V-RNA quantification by qRT-PCR, a common method used to determine viral replication and virus release from infected cells into the cell culture media. The TherOZap™ technology encompasses specialized coatings, light, heat, and solutions with possible antimicrobial properties that were tested for efficacy against the Zika virus (\"ZIKV\"). The summary and conclusions of the study are as follows:Treatment with the TherOZap™ technology was able to decrease vRNA in the media of infected cells, and decrease the CPE of infected cells over time.Treatment with the TherOZap™ technology without the use of specialized coatings was able to decrease CPE for a greater range of infectious doses of ZIKV.Treatment with the TherOZap™ technology without the use of specialized coatings reduced vRNA in the media of infected cells for a greater range of infectious doses of ZIKV.The vRNA decrease was dose dependent on the length of TherOZap™ technology treatment.Both the TherOZap™ technology with and without the use of specialized coatings decreased CPE and vRNA in a manner that correlated to the length of treatment time.The dose dependent effect of treatment strengthens the confidence of the conclusion that the TherOZap™ technology treatment was able to decrease the detection of vRNA and the possibility of antiviral effects of the TherOZap™Testing of solutions varied in dilution and specified dilutions may not have been optimal for testing. Further invest...